Prospects and Challenges for Alzheimer Therapeutics
Reference187 articles.
1. An effector-reduced anti-beta-amyloid (Abeta) antibody with unique Abeta binding properties promotes neuroprotection and glial engulfment of Abeta;Adolfsson;J Neurosci,2012
2. Tramiprosate in mild-to-moderate Alzheimer’s disease—a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study);Aisen;Arch Med Sci,2011
3. A phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease;Aisen;Neurology,2006
4. Pharmacodynamics of selective inhibition of gamma-secretase by avagacestat;Albright;J Pharmacol Exp Ther,2013
5. Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats;Arnt;Int J Neuropsychopharmacol,2010
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献